Efavirenz: A review of the epidemiology, severity and management of neuropsychiatric side-effects

R Gaida,1 MPharm; I Truter,1,2 DCom, BPharm, MSc, PhD; C Grobler,3 MB ChB, DOH, FCPSych, MMed (Psych), MD

1 Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
2 Drug Utilisation Research Unit, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
3 Department of Psychology, Nelson Mandela Metropolitan University; Elizabeth Donkin Hospital, Port Elizabeth, South Africa

Corresponding author: I Truter (ilse.truter@nmmu.ac.za)

South Africa has the highest proportion of HIV-positive people in the world. HIV cannot be cured; however, there are several major classes of drugs used in its management. Efavirenz is one such agent of the class non-nucleoside reverse transcriptase inhibitors which inhibits the replication of the virus. Efavirenz is associated with causing neuropsychiatric side-effects (NPSEs), with almost 50% of patients experiencing at least one NPSE while on treatment. The NPSEs tend to occur within the first few days of initiation of therapy and resolve spontaneously within the first 4 - 6 weeks, with the most commonly reported being dizziness, insomnia, headache, abnormal dreams and impaired concentration. The plasma level of efavirenz and genetic polymorphisms are thought to play a role in the development of such NPSEs. NPSEs need to be treated according to severity. If necessary, efavirenz may be replaced with nevirapine or lopinavir/ritonavir. It should be remembered that nevirapine may also produce some severe side-effects such as skin abnormalities and hepatotoxicity. The monitoring of patients receiving efavirenz therapy should be ongoing, with those with a history of mental illness requiring closer monitoring than others.


Antiretrovirals used in the management of HIV

HIV cannot be cured; however, there are several major classes of drugs used in its management. The five classes of drugs used for the management of HIV are entry inhibitors, fusion inhibitors, integrase inhibitors, protease inhibitors and reverse transcriptase inhibitors (nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors). These agents act through various mechanisms to stop the replication of HIV. The recommended regimens for the management of HIV in SA are summarised in Table 1.

Efavirenz is a non-nucleoside reverse transcriptase inhibitor that produces its antiretroviral activity by binding directly to the enzyme reverse transcriptase, thus inhibiting replication of the virus. Efavirenz possesses a long half-life of 40 - 55 hours and is predominantly metabolised in the liver by the CYP450 enzyme system. The specific isoform within the system most important for the metabolism of efavirenz is CYP2B6. Almost 50% of patients on efavirenz experience at least one NPSE. In spite of this, efavirenz is part of the first-line regimen of HIV management in SA. The NPSEs tend to occur within the first few days after initiation of therapy and then resolve spontaneously within the first 4 - 6 weeks. The most commonly reported NPSEs are dizziness, insomnia, headache, abnormal dreams and impaired concentration. An increased risk of suicidality has been a concern with efavirenz; however, there is conflicting opinion regarding this. In light of this, patients with an active psychiatric illness being considered for efavirenz therapy should be evaluated in terms of suicide risk, and these patients should be closely monitored after the initiation of therapy.

HIV infection is now regarded as a ‘chronic’ condition therefore, it is important to understand the long-term effects of efavirenz. Studies have been done to assess the long-term effects and have shown that NPSEs may persist for up to 2 - 3 years following initiation of efavirenz. Dizziness, sleep disturbances, abnormal dreams and light-headedness were the persisting symptoms. The 2010 Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents in South Africa stated that the recommended safety monitoring for the NPSEs of efavirenz is ‘clinical’. The term ‘clinical’ is left open to interpretation with no specific symptoms that should be taken into account when considering a diagnosis being listed. This indicates that it is the responsibility of the clinician to determine whether or not side-effects constitute a clinical change in the patient's condition and what management strategies need to be implemented. These Guidelines also advise that efavirenz should be...
avoided in patients with untreated depression and patients receiving psychoactive drugs. The 2014 Guidelines warn that efavirenz may cause persistent central nervous system toxicity such as abnormal dreams, depression or mental confusion, and that these side-effects are more likely to occur in patients with current or previous depression or other mental disorder or if the efavirenz is taken during the day. The efavirenz package insert does not state that efavirenz is contraindicated in psychiatric patients. It does, however, mention that efavirenz can cause NPSEs, although the incidence is stated as rare and includes only the following symptoms: anxiety, apathy, emotional lability, euphoria, hallucinations and depression.

Epidemiology of neuropsychiatric effects
The three main risk factors for the development of NPSEs in HIV-positive patients are: pre-existing mental conditions, HIV disease progression and ART. The plasma level of efavirenz is thought to play a role in the development of NPSEs, as are genetic polymorphisms in certain population groups.

Plasma level
The plasma level of efavirenz seems to have a place in predicting the incidence of NPSEs since the stepwise dosing of efavirenz is shown to decrease both the incidence and severity of NPSEs. However, studies attempting to determine the exact plasma level above which patients are at risk of developing these NPSEs have produced inconsistent data.

Genetic polymorphisms
Efavirenz is predominantly metabolised by the CYP450 enzyme system, specifically by the CYP2B6 isofrom. This enzyme is highly susceptible to polymorphism and these polymorphs play a role in the variability of efavirenz plasma concentrations. Functionally deficient alleles may result in higher plasma levels of efavirenz in patients receiving a standard dose of 600 mg daily because of decreased metabolism of efavirenz. The frequency of these deficient alleles varies among populations, but has been shown to be more common in patients of African descent. Such patients should therefore be monitored more closely as they are more likely to experience a higher plasma level of efavirenz and be susceptible to NPSEs. In an SA context, there are patients who possess the allelic variations, but there is no evidence to suggest that patients would benefit from routine genotyping and measurement of efavirenz plasma levels in terms of therapeutic outcomes. Therefore the current doses are sufficient.

Comparative studies between efavirenz and other antiretrovirals
Studies have been conducted comparing the incidence of NPSEs caused by efavirenz and other antiretroviral agents. Efavirenz has been compared with nevirapine, protease inhibitors, etravirine and raltegravir. All of these studies analysed have shown that the virological efficacy of efavirenz is not inferior to any other regimen. Although efavirenz demonstrated a higher incidence of NPSEs in all cases, the symptoms tended to be mild and necessitated discontinuation in only small numbers of patients. However, the studies noted that there were incidences of delayed onset of NPSEs associated with efavirenz, which refer to patients who develop these NPSEs approximately 1 year after efavirenz has been initiated. This means that patient monitoring needs to be a continuous process. One study stated that the only side-effects that did resolve were the neurological side-effects as the psychiatric side-effects were not generally identified and addressed by physicians. It was suggested that the psychiatric status of patients initiated on efavirenz be closely monitored more closely as they are more likely to experience a higher plasma level of efavirenz and be susceptible to NPSEs. In an SA context, there are patients who possess the allelic variations, but there is no evidence to suggest that patients would benefit from routine genotyping and measurement of efavirenz plasma levels in terms of therapeutic outcomes. Therefore the current doses are sufficient.

Table 1. Standardised first-line antiretroviral therapy regimens for adults and adolescents in SA

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Regimen</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adolescents &gt;15 years and weighing &gt;40 kg Adults All TB co-infection All hepatitis B virus co-infection</td>
<td>Tenofovir + lamivudine (or emtricitabine) + efavirenz to be provided as a fixed-dose combination</td>
<td>Replace efavirenz with nevirapine in patients with significant psychiatric comorbidity or intolerance to efavirenz and where the neuropsychiatric toxicity of efavirenz may impair daily functioning, e.g. shift workers</td>
</tr>
<tr>
<td>Adults and adolescents on stavudine</td>
<td>Change stavudine to tenofovir (no patient should be on stavudine)</td>
<td>Switch to tenofovir if virally suppressed and the patient has normal creatinine clearance, even if stavudine is well tolerated. If the viral load is &gt;1 000 copies/mL, manage as treatment failure and consider switching to second line</td>
</tr>
<tr>
<td>Adolescents &lt;15 years or weight &lt;40 kg</td>
<td>Abacavir + lamivudine + efavirenz</td>
<td>If adolescent weight &lt;40 kg, align with paediatric regimen</td>
</tr>
<tr>
<td>Contraindications to efavirenz:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Significant psychiatric comorbidity Impairment of daily function</td>
<td>Tenofovir + emtricitabine (or lamivudine) + nevirapine or lopinavir/ritonavir</td>
<td>If CD4 &lt;250 cells/mm³ (females) and &lt;400 cells/mm³ (males), give nevirapine 200 mg daily for 2 weeks, then 200 mg twice daily If CD4 ≥250 cells/mm³ (females) and ≥400 cells/mm³ (males), use lopinavir/ritonavir (two tablets 12 hourly)</td>
</tr>
<tr>
<td>Contraindications to tenofovir:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine clearance of &lt;50 mL/min</td>
<td>Abacavir + lamivudine + efavirenz (or nevirapine)</td>
<td>Renal disease or the use of other nephrotoxic drugs, e.g. aminoglycosides Multidrug-resistant TB treatment</td>
</tr>
</tbody>
</table>

TB = tuberculosis.
monitored for at least the first 6 months to 1 year of treatment. Specific patients who should be monitored are those with early neurological side-effects, as well as those with a history of psychiatric disorders or substance abuse. For patients who are in hospital environments, daily mental status evaluations should be performed. For patients in outpatient settings, evaluations should be performed at every visit for at least 1 year after the initiation of efavirenz.

**Severity of NPSEs**

The severity of NPSEs may negatively influence the adherence of patients to efavirenz therapy. Studies generally show that the symptoms are mild and do not warrant the discontinuation of efavirenz. It has, however, been stated that if the side-effects persist, patient adherence may decline over time regardless of whether or not the NPSEs are mild to moderate in severity. Ongoing patient counselling and monitoring is thus imperative for patients using efavirenz, as it is for all patients on ART.

**Management of NPSEs**

The Clinical Guidelines for the Management of HIV and AIDS in Adults and Adolescents in South Africa do not discuss the management of NPSEs caused by efavirenz in depth. Studies show that efavirenz is discontinued in patients who are unable to tolerate the side-effects. It is not indicated whether or not another antiretroviral agent is substituted in its place or if efavirenz is reinstituted once the side-effects have resolved. The Clinical Guidelines state that an acute psychotic episode should be managed according to the Standard Treatment Guidelines, which recommend that an acute psychotic episode be managed with 2 - 5 mg of haloperidol administered intramuscularly, to be repeated in 60 minutes if required. If the response to haloperidol is poor, a benzodiazepine such as lorazepam may be administered intramuscularly at a dose of 1 - 4 mg.

The NPSEs caused by efavirenz should be treated according to severity. Mild symptoms can be monitored and treated pharmacologically if necessary, whereas more severe symptoms may warrant the discontinuation of efavirenz and the addition of an alternative antiretroviral agent. Patients with a history of depression should receive antidepressant therapy before the initiation of ART or concurrently. If depression occurs after the initiation of efavirenz and does not resolve spontaneously, alternative ART (as ART is always a combination of three agents) or aggressive antidepressant treatment may need to be considered. Depression may be treated with selective serotonin reuptake inhibitors such as citalopram, escitalopram or fluoxetine. If a patient experiences acute psychosis, antipsychotic agents are safe to use. These agents should always be used at the lowest possible dose for the shortest duration possible. Generally, typical antipsychotic agents such as haloperidol or chlorpromazine are used in resource-limited settings. The patients should be monitored for extrapyramidal symptoms. If risperidone, an atypical antipsychotic, is available, it may be used at a dose of 1 - 4 mg daily. Atypical antipsychotics are recommended over typical antipsychotics as they are better tolerated, but this does not mean that they are without side-effects. Atypical antipsychotics are associated with long-term metabolic effects and the potential for drug interactions. Patients who have been experiencing NPSEs with efavirenz for years may be treated symptomatically if necessary.

The patient may still be on efavirenz because the patient finds the side-effects tolerable. Indeed, one of the studies that demonstrated delayed onset or persistence of NPSEs indicates that the long-term effects may be mild and tolerated well by patients.

Nevirapine may be substituted for efavirenz if the patient finds the NPSEs intolerable. Research has shown that this substitution will result in the resolution of NPSEs. However, there are safety concerns with nevirapine in terms of skin abnormalities and hepatitis, which is a life-threatening reaction. Patients being initiated on nevirapine need to be reviewed during the first weeks, as recommended by the Guidelines. The other alternative as indicated by the Guidelines is lopinavir/ritonavir. Moreover, there are significant drug interactions between ritonavir and psychotropic drugs such as clozapine, carbamazepine, and sedatives and hypnotics such as diazepam, midazolam and zolpidem. This would result in further problems in managing the psychiatric patient and the benefits should be weighed against the potential risks before initiating this agent. Other options would be the integrase-inhibitor raltegravir or the non-nucleoside reverse transcriptase inhibitor rilpivirine. Virological failure is more prevalent with rilpivirine than efavirenz, but the side-effect profile of rilpivirine is superior to efavirenz, specifically in terms of NPSEs.

Currently, clinical practice does not favour the prescribing of efavirenz to patients with pre-existing psychiatric conditions, which may compromise the quality of virological control. It is interesting to note that the Guidelines state that efavirenz is contraindicated in patients with an active psychiatric illness and nevirapine or lopinavir/ritonavir should be considered instead. Considering that NPSEs of efavirenz are not generally severe enough to warrant the discontinuation of the medicine, there is cause for reconsideration of this matter. Improved compliance may be possible with use of the fixed-dose combination in patients with an active psychiatric illness in order to reduce an extensive pill burden, as well as improved virological control.

**Declaration.** We declare that we have no financial or personal relationships which may have inappropriately influenced us in writing this paper.

**References**


